Effect of anti-HLA antibodies on mRNA and miRNA expression in HK-2 cells: a preliminary study
Abstract
Purpose: This study aimed to address the limited understanding of complement-associated molecular mechanisms in antibody-mediated rejection (ABMR) by evaluating ABMR-related mRNA and miRNA expression in an in vitro HK-2 cell model exposed to donor-specific anti-HLA antibodies.
Materials and Methods: We used the HK-2 cell line derived from normal kidney epithelial cells. An end-stage renal disease patient with HLA class I donor specific antibody, who was registered on the kidney waiting list for a positive serum [DSA(+)] and a healthy male without blood transfusion [negative control DSA (-)] were included in the study. The model includes both complement-dependent cytotoxicity (CDC) with and without complement in cell culture. Then, immune response–related mRNA and miRNA expression levels were evaluated by qRT-PCR.
Results: mRNA and miRNA expression levels were analyzed by qRT-PCR, revealing pronounced dysregulation in the DSA(+) CDC C(+) group. Let-7c-5p and miR-155 were markedly upregulated (~10³–10⁴-fold), whereas miR-21, miR-217, miR-145, miR-125a-5p, and miR-885 were downregulated (~10⁻²–10⁻⁴-fold). At the mRNA level, strong upregulation of TGF-β (~50-fold), TNF-α (~10-fold), and caspase-3 (~10-fold) was observed, while C1qB was markedly downregulated (~0.1-fold). Additionally, differences in the expression of TNF-α, C1qB and several miRNAs (miR-142-5p, miR-155, miR-125a-5p, miR-21, miR-29b-3p, miR-145, and miR-217) were detected between CDC complement C(−) and C(+) conditions.
Conclusion: This study presents the initial characterization of an in vitro ABMR model using kidney tubule epithelial cells and donor specific anti-HLA–A2 (+) serum. Furthermore, this is the first allorecognition model that assesses both C1q mRNA and certain miRNA expressions linked to antibody mediated rejection simultaneously.
Keywords
Anti-HLA Antibodies, miRNA, Expression, Kidney cell
Project Number
Project number 2022-TDR-SABE-0009.
References
- Chadban SJ, Ahn C, Axelrod DA, Foster BJ, Kasiske BL, Kher V et.al. KDIGO clinical practice guideline on the evaluation and management of candidates for kidney transplantation. Transplantation. 2020;104(+S1 Suppl 1):S11-103.
- Peng B, Zhuang Q, Yu M, Li J, Liu Y, Zhu L et al. Comparison of physical crossmatch and virtual crossmatch to identify preexisting donor-specific human leukocyte antigen (HLA) antibodies and outcome following kidney transplantation. Med Sci Monit. 2019;25:952-61.
- Heeger PS, Haro MC, Jordan S. Translating B cell immunology to the treatment of antibody-mediated allograft rejection. Nat Rev Nephrol. 2024;20:218-232.
- Erdogmus S, Şengül Ş. Immunologic risk assessment before kidney transplantation: an update. Turk J Nephrol. 2019;28:216-24.
- Matz M, Heinrich F, Lorkowski C, Wu K, Klotsche J, Zhang Q et al. MicroRNA regulation in blood cells of renal transplanted patients with interstitial fibrosis/tubular atrophy and antibody-mediated rejection. PLoS One. 2018;13:e0201925.
- Jeong HJ. Diagnosis of renal transplant rejection: Banff classification and beyond. Kidney Res Clin Pract. 2020;39:17-31.
- Heinemann FM, Jindra PT, Bockmeyer CL, Zeuschner P, Wittig J, Höflich H et al. Glomerulocapillary miRNA response to HLA-class I antibody in vitro and in vivo. Sci Rep. 2017;7:14554.
- Alwahaibi NY, Alissaei HK, Alshihi SA, Alabri N, Albalushi SS et al. Serum levels of TNF-α, IL-6, and IL-10 in hemodialysis and renal transplant patients and in healthy subjects. Portuguese Journal of Nephrology & Hypertension. 2016;30:194-8.
- Kir HM, Eraldemir C, Dervisoglu E, Caglayan C, Kalender B. Effects of chronic kidney disease and type of dialysis on serum levels of adiponectin, TNF-alpha and high sensitive C-reactive protein. Clin Lab. 2012;58:495-500.
- Avci E, Avci GA, Ozcelik B, Cevher SC, Suiçmez M. Transforming growth factor beta-1 An important biomarker for developing cardiovascular diseases in chronic renal failure. Bratisl Lek Listy. 2017;118:175-8.
